<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Obstetric%20Medicine/Hypertensive%20Disorders%20of%20Pregnancy/">
    <link rel="shortcut icon" href="../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Hypertensive disorders of pregnancy - MedNotes</title>
    <link href="../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../js/jquery-3.2.1.min.js"></script>
    <script src="../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Hypertensive disorders of pregnancy", url: "#_top", children: [
              {title: "HTN Definitions in Pregnancy", url: "#htn-definitions-in-pregnancy" },
              {title: "BP Targets in Pregnancy", url: "#bp-targets-in-pregnancy" },
              {title: "BP Medications in Pregnancy", url: "#bp-medications-in-pregnancy" },
          ]},
          {title: "Preeclampsia", url: "#preeclampsia", children: [
              {title: "Diagnosis/Definition", url: "#diagnosisdefinition" },
              {title: "Prevention of Pre-eclampsia", url: "#prevention-of-pre-eclampsia" },
              {title: "Treatment of Pre-eclampsia", url: "#treatment-of-pre-eclampsia" },
              {title: "Post-Partum Care", url: "#post-partum-care" },
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Thrombocytopenia%20in%20Pregnancy/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Thrombocytopenia%20in%20Pregnancy/" class="btn btn-xs btn-link">
        Thrombocytopenia in Pregnancy
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Diabetes%20in%20Pregnancy/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Diabetes%20in%20Pregnancy/" class="btn btn-xs btn-link">
        Diabetes in Pregnancy
      </a>
    </div>
    
  </div>

    

    <h1 id="hypertensive-disorders-of-pregnancy">Hypertensive disorders of pregnancy</h1>
<p>Spectrum/categories of HDP:</p>
<ol>
<li><strong>pre-existing HTN</strong> (prior to 20 weeks GA)</li>
<li><strong>GHTN</strong> (after 20 weeks GA)</li>
<li><strong>Transient HTN</strong> (single measurement)</li>
<li><strong>de novo preeclampsia</strong> (new or worsening hypertension with adverse conditions, usually after 20 weeks)</li>
</ol>
<h2 id="htn-definitions-in-pregnancy">HTN Definitions in Pregnancy</h2>
<table>
<thead>
<tr>
<th>Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Office measurement ≥140/90, ambulatory measurement ≥135/85</td>
</tr>
<tr>
<td>Severe hypertension</td>
<td>≥160/110</td>
</tr>
<tr>
<td>Resistant hypertension</td>
<td>≥3 anti-hypertensives</td>
</tr>
</tbody>
</table>
<h2 id="bp-targets-in-pregnancy">BP Targets in Pregnancy</h2>
<ol>
<li>Hypertension Canada: DBP &lt; 85 mmHg</li>
<li><strong>CHIPS (NEJM 2015) trial</strong>: "less tight" (target DBP 100 mm Hg) vs "tight" (target DBP 85 mm Hg) BP control in women with nonproteinuric pre-existing or gestational HTN.<ol>
<li>No difference in maternal or fetal outcomes</li>
<li>Higher severe hypertension in the less tight group (40 vs 28%) and had more laboratory features of HELLP</li>
</ol>
</li>
</ol>
<h2 id="bp-medications-in-pregnancy">BP Medications in Pregnancy</h2>
<p><img alt="" src="../_attachments/Pasted%20image%2020230121152736.png" />
<img alt="" src="../_attachments/Pasted%20image%2020230121152812.png" />
<img alt="" src="../_attachments/Pasted%20image%2020230121152821.png" /></p>
<h1 id="preeclampsia">Preeclampsia</h1>
<p>This is a multi system disorder in pregnancy that is mediated by the placenta, that results in systemic vascular and endothelial dysfunction, resulting in maternal and fetal morbidity and mortality.</p>
<p>Risk factors: first pregnancy, new partner, IVF, family history, age &lt;20 or &gt;35.
Maternal risk factors: prior pre-eclampsia, chronic HTN, DM, renal disease, autoimmune disorders, <a href="../../Endocrinology/Obesity/Obesity/">obesity</a>.
Fetal risk factors: multiple gestation, hydrops fetalis, molar pregnancy.</p>
<h2 id="diagnosisdefinition">Diagnosis/Definition</h2>
<ol>
<li>Hypertension as above.</li>
<li>Gestational age &gt; 20 weeks</li>
<li>Adverse conditions with end-organ damage or severe complications that warrant delivery and IV MgSO4 (see below)</li>
</ol>
<table>
<thead>
<tr>
<th>System</th>
<th>Adverse condition</th>
<th>Severe Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS</td>
<td>HA/visual symptoms</td>
<td>eclampsia, PRES, cortical blindness, GCS &lt;13, stroke, TIA, RIND</td>
</tr>
<tr>
<td>Cardiorespiratory</td>
<td>Chest pain or dyspnea, SpO2 &lt; 97%</td>
<td>Uncontrolled severe HTN, frank hypoxia or respiratory failure, infarction, pulmonary edema and heart failure</td>
</tr>
<tr>
<td>Hematologic</td>
<td>Leukocytosis, coagulopathy, thrombocytopenia</td>
<td>Plt &lt; 50, blood product transfusion</td>
</tr>
<tr>
<td>Renal</td>
<td>Elevated Cr, hyperuricemia</td>
<td>AKI, dialysis</td>
</tr>
<tr>
<td>Hepatic</td>
<td>N/V, RUQ or epigastric pain, elevated liver enzymes or decreased liver synthetic function</td>
<td>liver dysfunction (INR &gt; 2), hepatic hematoma or capsular rupture</td>
</tr>
<tr>
<td>Feto-placental</td>
<td>AbN FHR, IUGR, oligohydramnios, absent or reversed end-diastolic flow (Dopplers)</td>
<td>placental abruption, reverse ductus venosus A wave</td>
</tr>
</tbody>
</table>
<h2 id="prevention-of-pre-eclampsia">Prevention of Pre-eclampsia</h2>
<ul>
<li><strong>ASA</strong> 81-162 mg daily<ul>
<li>this was examined in the <strong>ASPREE</strong> trial (NEJM 2017) which randomized women to ASA 150 mg vs placebo, and showed that this intervention reduced pre-eclampsia &lt;37 weeks (1.6% vs 4.3%)</li>
<li><em>start 12-16 weeks and continue until 36 weeks</em></li>
<li>Indications per the USPTF: prior pre-eclampsia, chronic HTN, DM1 or DM2, CKD, SLE, APLA, multiple gestation, two or more minor factors (such as nulliparous or new partner, IVF, Age &gt; 35, BMI &gt; 30, first-degree family history of pre-eclampsia)</li>
</ul>
</li>
<li><strong>Calcium</strong> 1000 mg daily supplementation recommend ed if low dietary intake (&lt;600 mg)</li>
<li><strong>APLA testing</strong><ul>
<li>diagnostic criteria<ul>
<li>obstetric event: 3 pregnancy losses &lt;10 weeks, 1 pregnancy loss &gt; 10 week, 1 preterm pre-eclampsia &lt;34 weeks</li>
<li>arterial or venous thrombosis</li>
<li>laboratory criteria</li>
</ul>
</li>
<li>if obstetric criteria, treat with ASA +/- prophylactic dose LMWH</li>
</ul>
</li>
</ul>
<h2 id="treatment-of-pre-eclampsia">Treatment of Pre-eclampsia</h2>
<h3 id="1-hypertension-management">1 - Hypertension Management</h3>
<ul>
<li>Note: this doesn't prevent progression of pre-eclampsia.</li>
<li>See above for BP management in pregnancy.</li>
</ul>
<h3 id="2-eclampsia-prevention">2 - Eclampsia Prevention</h3>
<ul>
<li><strong>IV magnesium sulfate</strong> is the medication of choice<ul>
<li>Informed by the <strong>Magpie (Lancet 2002) trial</strong> which randomized 10,000 women with pre-eclampsia to Mg vs placebo. It showed a 58% RRR NNT 91 reduction in eclampsia, and trend towards decreased mortality.</li>
<li>Therefore IV MgSO4 is indicated for the prevention and treatment of eclampsia.<ul>
<li>Preventative indications: severe pre-eclampsia, severe HTN, headache, vision changes, RUQ plain, thrombocytopenia, elevated liver enzymes, AKI</li>
<li>Treatment indications: first-line for seizures in pregnancy which are related to eclampsia.</li>
</ul>
</li>
<li>Regimen: <em>4g IV loading dose then 1-2 g/hr for at least 24 hours after delivery</em>. Requires a Foley (everyone) and a monitored setting</li>
<li>Toxicity of IV MgSO4:<ul>
<li>Symptoms: respiratory suppression, bradycardia, hypotension, reduced GCS and CNS suppression</li>
<li>Monitoring: decreased tendon reflexes, decreased UOP. NOT by monitoring Mg levels.</li>
<li>Treatment: stop Mg, IV calcium gluconate, and consider RRT</li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 id="3-delivery">3 - Delivery</h3>
<ul>
<li>decision is made by the OB (involve them early!)</li>
<li>indications for delivery are generally<ul>
<li>severe pre-eclampsia</li>
<li>refractory maternal symptoms (resistant HTN, persistent symptoms, and end-organ damage)</li>
<li>fetal complications: IGUR, Doppler abnormalities, fetal distress</li>
<li>women at term: &gt;37 weeks GA</li>
</ul>
</li>
<li><strong>antenatal corticosteroids for fetus &lt;35 weeks GA</strong> (betamethasone). <a href="https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/antenatal-corticosteroid-therapy-for-fetal-maturation">Per the ACOG</a>:<ul>
<li>A single course of corticosteroids is recommended for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation who are at risk of preterm delivery within 7 days, including for those with ruptured membranes and multiple gestations. It also may be considered for pregnant women starting at 23 0/7 weeks of gestation who are at risk of preterm delivery within 7 days, based on a family’s decision regarding resuscitation, irrespective of membrane rupture status and regardless of fetal number</li>
<li>Administration of corticosteroids for pregnant women during the periviable period who are at risk of preterm delivery within 7 days is linked to a family’s decision regarding resuscitation and should be considered in that context</li>
<li>A single course of betamethasone is recommended for pregnant women between 34 0/7 weeks and 36 6/7 weeks of gestation at risk of preterm birth within 7 days, and who have not received a previous course of antenatal corticosteroids.</li>
<li>Regularly scheduled repeat courses or serial courses (more than two) are not currently recommended.</li>
<li>A single repeat course of antenatal corticosteroids should be considered in women who are less than 34 0/7 weeks of gestation who are at risk of preterm delivery within 7 days, and whose prior course of antenatal corticosteroids was administered more than 14 days previously. Rescue course corticosteroids could be provided as early as 7 days from the prior dose, if indicated by the clinical scenario.</li>
</ul>
</li>
<li>pre-eclampsia is not a contraindication for vaginal delivery</li>
<li>epidurals are safe when Plt &gt; 75 and without coagulopathy</li>
</ul>
<h2 id="post-partum-care">Post-Partum Care</h2>
<ol>
<li>BP tends to rise 3-6 days post-partum</li>
<li>Pre-eclampsia puts women at 4x increased risk of chronic HTN, 2x increased risk of heart disease, stroke, VTE, and diabetes. <em>Make sure to counsel the patient about future pregnancy risk, CVD risk, and to quit smoking, lose weight, and support breastfeeding</em></li>
<li>ACE inhibitors are safe in breast feeding</li>
</ol>
<h1 id="references">References</h1>
<ol>
<li>IMR Slides (2021)</li>
<li>CHIPS trial</li>
<li>Magpie trial</li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Thrombocytopenia%20in%20Pregnancy/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Thrombocytopenia%20in%20Pregnancy/" class="btn btn-xs btn-link">
        Thrombocytopenia in Pregnancy
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Diabetes%20in%20Pregnancy/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Diabetes%20in%20Pregnancy/" class="btn btn-xs btn-link">
        Diabetes in Pregnancy
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>